MPM Bioimpact LLC Makes New $10.64 Million Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

MPM Bioimpact LLC purchased a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 414,035 shares of the company's stock, valued at approximately $10,641,000. MPM Bioimpact LLC owned about 0.48% of IDEAYA Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of IDYA. Janus Henderson Group PLC boosted its holdings in IDEAYA Biosciences by 13.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after acquiring an additional 695,263 shares during the period. Norges Bank purchased a new position in IDEAYA Biosciences during the 4th quarter valued at $13,385,000. FMR LLC boosted its holdings in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after acquiring an additional 327,498 shares during the period. Vanguard Group Inc. boosted its holdings in IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after acquiring an additional 282,936 shares during the period. Finally, WCM Investment Management LLC purchased a new position in IDEAYA Biosciences during the 4th quarter valued at $6,030,000. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded up $0.51 during mid-day trading on Friday, reaching $17.82. 1,150,677 shares of the company were exchanged, compared to its average volume of 999,402. The business has a fifty day moving average of $17.64 and a 200 day moving average of $22.27. The firm has a market cap of $1.56 billion, a P/E ratio of -5.40 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm posted ($0.53) earnings per share. Sell-side analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $54.27.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.